Introduction
Glycaemia in type 2 diabetes is difficult to manage advent of symptoms before additional pharmacological agents were introduced. The epidemiology long-term, and despite a wealth of epidemiological analysis of the UKPDS suggested that there was no evidence, there continued to be doubts, until discernible threshold for the improved outcome with recently, as to whether intensive glucose control was lower glycaemia. beneficial. The publication of robust prospective However, in clinical practice optimal glycaemic evidence from the United Kingdom Prospective control is difficult to obtain. Prospective randomized Diabetes Study1 in September 1998 marked a studies have achieved median HbA1c levels of 7.1%5 seminal change. and 7.0% in intensively treated patients,1 but, by In type 2 diabetes, there was extensive epidemioldefinition, 50% of the patients must have had values ogical data suggesting that complications were linked above this level. to glycaemic exposure,2 but the UGDP (University The reasons for poor glycaemic control are comGroup Diabetes Program)3 trial had raised doubts plex, and relate to the disease process itself, the about the safety of sulphonylureas in reducing plasma inadequacy of therapeutic regimens and the attitudes glucose. The DCCT4 showed in 1993 that tight of both doctors and patients. We discuss here some glycaemic control reduced microvascular complicaof the factors related to poor control, and propose tions in type 1 diabetes. The UKPDS provided some views about the solutions to the problem. evidence that tight control was beneficial in type 2 diabetes: patients in an intensively treated group achieved a median HbA1c of 7.0% at 10 years compared to 7.9% in those in a conventionally Progressive decline of b-cell function treated group. This improvement in glycaemic control was associated with a 12% reduction in any diabetes One finding of the UKPDS was that fasting plasma end-points ( p=0.029) and a 25% reduction in glucose deteriorated with time. The deterioration in microvascular end-points ( p=0.0099).1 However the diet-only policy group strongly suggests that there the achieved HbA1c values of the trial were neither is progressive deterioration of b-cell function or an the aim of the trial, nor the best glycaemic control increase in insulin resistance over many years. A that could be achieved, because one of the aims parallel deterioration was shown in those on sulphonwas to address the question of the efficacy and safety ylurea or metformin, suggesting that neither of these of monotherapies. Thus the protocol required, in agents either accelerated or slowed the rate of those randomized to sulphonylurea therapy, that, decline. once the maximum dose was reached, the fasting A more detailed analysis of the problem can be undertaken using modelling techniques. b-Cell plasma glucose could rise to 15 mmol/l or to the function can be measured by the homeostasis model half of the patients deteriorated at the significantly faster rate of rate of 1.5 mmol/l/year. (HOMA),6 which showed a reduction from a mean of 50% function at diagnosis to 25% at 5 years. 7 Patients and physicians need to be aware that patients are likely to need the addition of other These HOMA estimates of failure rate are concordant with other published estimates.6,8 There is no current therapeutic agents at regular intervals1 and those with diabetes should be made aware at an early identified therapy that stops the decline in b-cell function and as b-cell function declines, glycaemia stage that the need for such augmentation does not represent 'failure' on their part, nor an unexpected increases. 'Sulphonylurea failure' is thus a misnomer: what is observed in the increasing glycaemia of type outcome. Physicians should avoid becoming complicit in an attempt to belittle type 2 diabetes in its 2 diabetes over the course of many years as a result of failure of the b cell, not the therapeutic agent. It early stages as a 'minor condition' which can 'easily be managed' by diet and tablets. Such an introducis also apparent that functional deterioration occurred in those patients in the UKPDS allocated to insulin, tion to diabetes leads to later disappointment or selfreproach. and is the explanation why, even when insulin was prescribed in appropriate doses, the HbA1c rose towards that achieved in the DCCT intensive group. This value, about 7%, is probably the best median Attempting to avoid polypharmacy or achievable HbA1c in those who have total binsulin treatment cell loss.
The rate of failure has been described in detail in Patients and physicians have often colluded in implithe UKPDS patients: failure of sulphonylurea therapy cit and unspoken contracts to continue oral agents is significantly greater in those who have a higher for as long as possible. Physicians prevaricate with fasting plasma glucose at diagnosis: in the UKPDS, a view that they are giving improvement of diet or 61% of those who had fasting glucose >10 mmol/l another effort at weight-loss one last chance. Patients at randomization required additional therapy at adopt optimistic views based on lack of symptoms 6 years, compared to 23% of those with a fasting or have pragmatic fears about the complexity of glucose <7.8 mmol/l ( p=0.00001). 9 insulin. Some patients even regard insulin therapy as In view of this progressive decline in b-cell a prelude to death-the medical equivalent of the function, it is essential to monitor diabetes on a last rites. regular basis in order to increase therapy approPatients' fears and medical reluctance need to be priately. In the UKPDS, the fasting plasma glucose overcome if appropriate therapy is to be delivered rose at a rate of approximately 0.2 mmol/l/year and and the complications of diabetes avoided. HbA1c at 0.2% per year (Figure 1 ). However in the It is clear from the UKPDS1 that many patients Belfast study,10 this relatively slow rate of increase will require multiple drug regimens, as well as an occurred only in those patients with the lowest mean escalation of dose over the years of their treatment. fasting plasma glucose at diagnosis (7.5 mmol/l) but This therapeutic plan needs to be explained early in the course of type 2 diabetes so that patients and physicians alike can discuss realistic glycaemic goals.
Avoiding hypoglycaemia
In the DCCT, intensive treatment was accompanied by a threefold increase in rate of hypoglycaemia ( p<0.001): 27% of patients in the intensively treated group experienced at least one episode of severe hypoglycaemia during the first year compared to 10% in the conventionally treated group.11 However, the high rates of hypoglycaemia in type 1 diabetes caemia (requiring help from another person) in those
The aim of treatment in the conventionally treated group on insulin and a much lower percentage rate for was to achieve a fasting plasma glucose <15 mmol/l those on oral agents (Figure 2) .
and/or to abolish symptoms of hyperglycaemia, whereas
Although the increased potential for hypoglyin the intensively treated group the aim was to achieve a fasting plasma glucose <6 mmol/l.1 caemic episodes with intensive treatment may limit of borderline significance ( p=0.052), although this may reflect the relatively short follow-up of 10 years, compared to the median life expectancy, at diagnosis, of 20 years (1). This raises the possibility of seeing a significant benefit if patients are followedup for longer. The benefits conferred by good control outweigh any theoretical and unsubstantiated disadvantages.
Concern over adverse cardiovascular effects from sulphonylureas
Despite previous concerns about the possibility of tolbutamide playing a role in preventing ischaemic preconditioning,3 the UKPDS did not show any deleterious effect of sulphonylureas on macrovascular end-points.1 not be the basis for mismanagement of patients, and local guidelines can be 'corrected' to the candidate reference method used in the DCCT as part of the the degree of control attainable, this should not deter US National Glycohaemoglobin Standardization clinicians and patients from attempting to achieve Program. Replication of the UKPDS results would tighter control. Appropriate oral therapy can miniminvolve measuring fasting plasma glucose at 3-month ize hypoglycaemia (glibenclamide caused more intervals, and adjusting therapy aiming to achieve a hypoglycaemia than chlorpropramide, and metforvalue of ∏6 mmol/l. The 'achieved' HbA1c of the min less than any sulphonylurea). There is no inher-UKPDS intensive policy group was not the 'aim'. ent reason why clinicians should be prepared for Indeed, by definition, 50% of patients had values some hypoglycaemia episodes in type 1 diabetes below the median. One would have to aim, and not in type 2-the aim of therapy is the same, namely to avoid complications by appropriate glycaemic management.
Concern over the possibility of increased macrovascular risk
Concern over the risk of atherogenicity due to high doses of insulin Many type 2 diabetic patients are overweight1 and insulin-resistant12 and so they may require high doses of insulin. This has led to concerns about possible atherogenic effects of insulin.13 The UKPDS showed myocardial infarction with intensive treatment was generally, lower than the median value if one were is associated on average with weight gain, and patients and physicians need to address the problem to achieve this goal in clinical practice. A pragmatic view should prevail: that any improvement of glyproactively. Patients should be told to reduce their insulin if they get recurrent hypoglycaemia rather caemia towards the normal levels is likely to reduce the risk of complications.
than increase food intake: snacks should be discouraged in those on long-acting insulin alone, and additional dietetic advice about reduction of total calorie intake may be necessary.
Weight gain
However, notwithstanding the weight gain in the Many type 2 diabetic patients are overweight at UKPDS patients, there was still a lower complication diagnosis; the mean body mass index of patients at rate with intensive treatment: of the two risks, weight entry to the UKPDS was 27.5 kg/m2,1 and patients gain is less dangerous than chronic hyperglycaemia. are worried about the role insulin therapy may play in causing further weight gain. Doctors are concerned about the risk of setting up a vicious circle of
Limitations of current technology
increasing weight and increasing insulin resistance with consequent deterioration in glycaemic control Although many patients find it much easier to inject and escalation of insulin doses.
insulin using a pen device, at present the maximum Patients assigned to intensive treatment gained a single dose delivered by a pen system is limited mean of 3 kg more than those assigned to convento 70 units. As many patients with type 2 diabetes tional treatment after 10 years: patients treated with are overweight and insulin-resistant, they may well insulin gained 4.0 kg more, those on chlorpropamide require doses in excess of 70 units, and the current gained 2.6 kg more, and those assigned to glibenclalimitations in technology should not deter physicians mide gained 1.7 kg more than those in the convenand patients from increasing insulin doses beyond 70 tional treatment group1 (Figure 4 ). Intensive treatment units as required. Higher doses can be delivered by dialling the dose in two stages or using vials and syringes. Physicians tend to become over-cautious in the use of insulin in doses >100 units/day, but insulin resistance generally prevents rapid swings of glycaemia, and hypoglycaemia in such patients is very rare.
The elderly
There are some caveats to the use of insulin: elderly patients may find the technology difficult, and failing eyesight and dexterity need to be taken into consideration. On the other hand, it is ironic that some old people will have failing eyesight simply because they were not appropriately treated with insulin. Physicians should be cautious of the ageist view of the elderly as frail, untrainable and liable to deteriorate in any event.
Unintentional non-compliance
Several studies have shown that admissions due to unintentional non-compliance occur with twice the frequency in the elderly (19%) compared to the 
Resources
Intensifying treatment in patients with type 2 diabetes at 12 years in UKPDS was 36 units of insulin, this figure is an underestimate of the doses needed in and treatment targets, limitations in currently availclinical practice, as in the study people with good able technology, ageist policies, and a lack of control were randomized to insulin and therefore resources. required lower doses than those patients started on
However the glycaemic objectives in type 2 diainsulin for poor glycaemic control. The annual cost betes should not differ from those in Type 1 diabetes, of a daily dose of 62 units (which represents the namely to aim to normalize glycaemia and HbA1c, mean daily dose of insulin in patients with type 2 minimize the risk of hypoglycaemia and avoid diabetes in our clinic), of Mixtard 30 compared to adversely affecting quality of life. the annual cost of a combination of metformin 1.5 g and gliclazide 320 mg is shown in Figure 5 .
In the long term, this increase in expenditure will
